{"id":"ribavirin-peg-interferon-alfa-2b","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Anemia"},{"rate":"60-70","effect":"Fatigue"},{"rate":"40-50","effect":"Headache"},{"rate":"30-40","effect":"Myalgia"},{"rate":"5-10","effect":"Neutropenia"},{"rate":"5-10","effect":"Thrombocytopenia"},{"rate":"20-30","effect":"Depression/mood changes"},{"rate":"30-40","effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ribavirin is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase and reduces viral replication. Peginterferon alfa-2b is a long-acting interferon that activates innate immunity and enhances antiviral T-cell responses. Together, they synergistically suppress HCV replication and promote viral clearance.","oneSentence":"Ribavirin and peginterferon alfa-2b work together to inhibit viral replication and enhance immune response against hepatitis C virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:06.226Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotype-dependent)"},{"name":"Hepatitis C in patients with compensated cirrhosis"}]},"trialDetails":[{"nctId":"NCT01353911","phase":"PHASE2","title":"Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-06-27","conditions":"Hepatitis C, Chronic","enrollment":368},{"nctId":"NCT01678131","phase":"PHASE1","title":"Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-30","conditions":"Chronic Hepatitis C","enrollment":31},{"nctId":"NCT03483987","phase":"NA","title":"Re-treatment of HCV Following DAA Failure","status":"TERMINATED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2018-02-10","conditions":"Chronic Hepatitis C","enrollment":18},{"nctId":"NCT04382937","phase":"PHASE3","title":"Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2016-01-12","conditions":"Chronic Hepatitis C Virus Infection","enrollment":222},{"nctId":"NCT01482767","phase":"PHASE3","title":"Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-04","conditions":"HIV Infections, Hepatitis C","enrollment":262},{"nctId":"NCT00015652","phase":"NA","title":"Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis C","enrollment":24},{"nctId":"NCT00381953","phase":"PHASE3","title":"High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2003-02","conditions":"Hepatitis C","enrollment":33},{"nctId":"NCT01710501","phase":"PHASE2","title":"A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-07","conditions":"Chronic Hepatitis C (CHC)","enrollment":87},{"nctId":"NCT00237484","phase":"PHASE3","title":"Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07-18","conditions":"Hepatitis C, Chronic","enrollment":89},{"nctId":"NCT01364090","phase":"PHASE4","title":"A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Hepatitis C, Chronic","enrollment":93},{"nctId":"NCT03833362","phase":"PHASE3","title":"Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2014-05-07","conditions":"Hepatitis C","enrollment":420},{"nctId":"NCT01606800","phase":"PHASE4","title":"Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-01","conditions":"Hepatitis C, Chronic","enrollment":45},{"nctId":"NCT00689390","phase":"PHASE2, PHASE3","title":"Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-02-20","conditions":"Hepatitis C, Chronic, Hepacivirus","enrollment":1954},{"nctId":"NCT01945294","phase":"PHASE3","title":"Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-10","conditions":"Hepatitis C, Chronic","enrollment":257},{"nctId":"NCT02099604","phase":"PHASE3","title":"Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C","status":"WITHDRAWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-04","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT00317746","phase":"PHASE3","title":"Trial of Citalopram for the Prevention of Depression","status":"COMPLETED","sponsor":"Marina Klein","startDate":"2006-11","conditions":"Depression, HIV Infections, Hepatitis C","enrollment":76},{"nctId":"NCT00493805","phase":"PHASE4","title":"Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-04","conditions":"Hepatitis C, Chronic, Insulin Resistance","enrollment":59},{"nctId":"NCT00423800","phase":"PHASE3","title":"Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12","conditions":"Hepatitis C, Chronic","enrollment":56},{"nctId":"NCT00708500","phase":"PHASE3","title":"Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":404},{"nctId":"NCT00686777","phase":"PHASE4","title":"Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01","conditions":"Hepatitis C, Chronic","enrollment":75},{"nctId":"NCT00863109","phase":"","title":"Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04","conditions":"Hepatitis C, Chronic, Genotype 1, HCV-1","enrollment":133},{"nctId":"NCT00255034","phase":"PHASE4","title":"Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-02","conditions":"Hepatitis C, Chronic","enrollment":146},{"nctId":"NCT00378599","phase":"PHASE3","title":"Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05","conditions":"Liver Transplantation, Hepatitis C, Chronic, Liver Cirrhosis","enrollment":125},{"nctId":"NCT00255008","phase":"PHASE4","title":"Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Hepatitis C, Chronic","enrollment":121},{"nctId":"NCT00202839","phase":"PHASE4","title":"Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Hepatitis C, Chronic","enrollment":160},{"nctId":"NCT00265395","phase":"PHASE3","title":"Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-12","conditions":"Hepatitis C, Chronic","enrollment":1428},{"nctId":"NCT00686517","phase":"PHASE3","title":"Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-12","conditions":"Hepatitis C","enrollment":130},{"nctId":"NCT00302081","phase":"PHASE3","title":"Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-08","conditions":"Hepatitis C, Chronic","enrollment":696},{"nctId":"NCT00441584","phase":"PHASE3","title":"The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07","conditions":"Hepatitis C, Chronic","enrollment":117},{"nctId":"NCT00104052","phase":"PHASE3","title":"Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-02","conditions":"Hepatitis C, Chronic","enrollment":107},{"nctId":"NCT00048724","phase":"PHASE3","title":"Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-06","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":631},{"nctId":"NCT00081770","phase":"PHASE3","title":"Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-03","conditions":"Hepatitis C, Chronic","enrollment":4469},{"nctId":"NCT00049842","phase":"PHASE3","title":"Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-10","conditions":"Chronic Hepatitis C, Liver Fibrosis","enrollment":540},{"nctId":"NCT00039871","phase":"PHASE3","title":"PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-05","conditions":"Hepatitis, Hepatitis C, Chronic, Fibrosis","enrollment":2333},{"nctId":"NCT00761735","phase":"PHASE3","title":"5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Hepatitis C, Chronic","enrollment":94},{"nctId":"NCT01447446","phase":"","title":"An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Hepatitis C, Chronic","enrollment":4442},{"nctId":"NCT00248339","phase":"PHASE3","title":"Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2002-05","conditions":"Hepatitis C","enrollment":150},{"nctId":"NCT00277238","phase":"PHASE2","title":"CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-02","conditions":"Hepatitis, Chronic Active","enrollment":113},{"nctId":"NCT00759200","phase":"PHASE2","title":"Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-10","conditions":"Chronic Hepatitis C","enrollment":525},{"nctId":"NCT01838772","phase":"PHASE4","title":"HCV Treatment in HIV Co-Infected Patients in Asia","status":"COMPLETED","sponsor":"amfAR, The Foundation for AIDS Research","startDate":"2013-12","conditions":"Hepatitis C, HIV","enrollment":188},{"nctId":"NCT00087607","phase":"PHASE4","title":"Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-01","conditions":"Hepatitis C, Chronic","enrollment":385},{"nctId":"NCT00087568","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-01","conditions":"Hepatitis C, Chronic","enrollment":57},{"nctId":"NCT00723645","phase":"","title":"Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-04","conditions":"Hepatitis C, Chronic","enrollment":279},{"nctId":"NCT01547312","phase":"PHASE1","title":"Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-05","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT00160251","phase":"PHASE2","title":"Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09","conditions":"Chronic Hepatitis C","enrollment":357},{"nctId":"NCT01573351","phase":"PHASE3","title":"Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C Virus","enrollment":398},{"nctId":"NCT02112630","phase":"NA","title":"Boceprevir in End Stage Renal Disease (ESRD)","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2013-05","conditions":"Hepatitis C Infection, End Stage Renal Disease","enrollment":""},{"nctId":"NCT00216775","phase":"","title":"Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C","status":"COMPLETED","sponsor":"Kyoto University","startDate":"2004-12","conditions":"Hepatitis C, Chronic","enrollment":50},{"nctId":"NCT00375661","phase":"PHASE4","title":"Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC","status":"COMPLETED","sponsor":"Kyoto University","startDate":"2006-09","conditions":"Hepatitis C, Chronic","enrollment":100},{"nctId":"NCT01443923","phase":"PHASE4","title":"Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-09","conditions":"Hepatitis, HIV/AIDS","enrollment":4},{"nctId":"NCT00856024","phase":"","title":"ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07","conditions":"Hepatitis C, Chronic","enrollment":902},{"nctId":"NCT01871662","phase":"PHASE2, PHASE3","title":"Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C","status":"WITHDRAWN","sponsor":"Rottapharm","startDate":"2013-08","conditions":"Hepatitis C, Chronic","enrollment":""},{"nctId":"NCT00724295","phase":"","title":"Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-04","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":1077},{"nctId":"NCT00709228","phase":"","title":"Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05","conditions":"Hepatitis C","enrollment":496},{"nctId":"NCT01054742","phase":"","title":"Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12","conditions":"Hepatitis C","enrollment":2},{"nctId":"NCT01405027","phase":"PHASE4","title":"Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy","status":"COMPLETED","sponsor":"Chronic Liver Disease Foundation","startDate":"2011-12","conditions":"Chronic Hepatitis C, Genotype 1","enrollment":197},{"nctId":"NCT01335529","phase":"PHASE2","title":"Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2011-05","conditions":"HCV Coinfection, HIV-1 Infection","enrollment":69},{"nctId":"NCT00018031","phase":"PHASE2","title":"Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-06","conditions":"Hepatitis C, HIV Infections","enrollment":36},{"nctId":"NCT00556504","phase":"PHASE2","title":"The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection","status":"COMPLETED","sponsor":"TCM Biotech International Corp.","startDate":"2007-07","conditions":"Chronic Hepatitis C","enrollment":84},{"nctId":"NCT00115908","phase":"PHASE2","title":"A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1","status":"COMPLETED","sponsor":"Human Genome Sciences Inc.","startDate":"2005-05","conditions":"Hepatitis C, Chronic","enrollment":458},{"nctId":"NCT01949168","phase":"PHASE2","title":"A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV","status":"UNKNOWN","sponsor":"St Vincent's Hospital Melbourne","startDate":"2013-09","conditions":"Chronic Hepatitis C","enrollment":30},{"nctId":"NCT01010646","phase":"PHASE2","title":"Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2010-03","conditions":"Chronic Hepatitis C","enrollment":84},{"nctId":"NCT00402428","phase":"PHASE3","title":"Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients","status":"COMPLETED","sponsor":"Human Genome Sciences Inc.","startDate":"2006-12","conditions":"Chronic Hepatitis C","enrollment":1331},{"nctId":"NCT00411385","phase":"PHASE3","title":"Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3","status":"COMPLETED","sponsor":"Human Genome Sciences Inc.","startDate":"2007-02","conditions":"Chronic Hepatitis C","enrollment":933},{"nctId":"NCT00135798","phase":"PHASE2","title":"Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2005-09","conditions":"Hepatitis C","enrollment":79},{"nctId":"NCT00367887","phase":"PHASE2","title":"A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-10","conditions":"Hepatitis C","enrollment":246},{"nctId":"NCT01025765","phase":"PHASE4","title":"The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2009-11","conditions":"Chronic Hepatitis C","enrollment":80},{"nctId":"NCT00279565","phase":"PHASE4","title":"Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED)","status":"TERMINATED","sponsor":"Indivior Inc.","startDate":"2005-08","conditions":"Hepatitis C, Chronic","enrollment":128},{"nctId":"NCT00502099","phase":"PHASE4","title":"Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4","status":"COMPLETED","sponsor":"Amr Hafez","startDate":"2006-01","conditions":"Hepatitis C","enrollment":217},{"nctId":"NCT01457937","phase":"PHASE3","title":"Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)","status":"UNKNOWN","sponsor":"University of Modena and Reggio Emilia","startDate":"2011-11","conditions":"Chronic Hepatitis C, Menopause","enrollment":240},{"nctId":"NCT01683786","phase":"PHASE4","title":"36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2011-08","conditions":"Hepatitis C Infection","enrollment":60},{"nctId":"NCT00446134","phase":"PHASE2","title":"Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2007-03","conditions":"Chronic Hepatitis C","enrollment":278},{"nctId":"NCT00207363","phase":"PHASE4","title":"Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC","status":"COMPLETED","sponsor":"Brooke Army Medical Center","startDate":"2002-02","conditions":"Hepatitis C","enrollment":610},{"nctId":"NCT00593151","phase":"PHASE1, PHASE2","title":"Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Biolex Therapeutics, Inc.","startDate":"2008-01","conditions":"Hepatitis C","enrollment":32},{"nctId":"NCT00863239","phase":"PHASE2","title":"Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV","status":"COMPLETED","sponsor":"Biolex Therapeutics, Inc.","startDate":"2009-03","conditions":"Hepatitis C, Chronic","enrollment":116},{"nctId":"NCT00953589","phase":"PHASE2","title":"480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"Biolex Therapeutics, Inc.","startDate":"2009-07","conditions":"Hepatitis C, Chronic","enrollment":74},{"nctId":"NCT01121705","phase":"PHASE3","title":"Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)","status":"COMPLETED","sponsor":"Casa Sollievo della Sofferenza IRCCS","startDate":"2007-01","conditions":"Chronic Hepatitis","enrollment":360},{"nctId":"NCT00308048","phase":"PHASE3","title":"14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response","status":"COMPLETED","sponsor":"Ullevaal University Hospital","startDate":"2004-03","conditions":"Hepatitis C Virus Infection","enrollment":435},{"nctId":"NCT00310336","phase":"PHASE2, PHASE3","title":"Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2006-08","conditions":"Hepatitis C","enrollment":30},{"nctId":"NCT01195181","phase":"PHASE4","title":"Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.","status":"COMPLETED","sponsor":"Azienda Ospedaliera di Padova","startDate":"2005-09","conditions":"Hepatitis C Virus, Chronic Liver Disease, Viral Hepatitis","enrollment":506},{"nctId":"NCT00956982","phase":"NA","title":"PEG-IFN Plus Ribavirin Combination Therapy for Older Patients","status":"UNKNOWN","sponsor":"Kyushu University","startDate":"2004-12","conditions":"Hepatitis C Virus","enrollment":1251},{"nctId":"NCT00059358","phase":"PHASE1, PHASE2","title":"Zidovudine Levels in HIV Infected Patients Being Treated for HCV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-09","conditions":"HIV Infections, Hepatitis C","enrollment":16},{"nctId":"NCT00084279","phase":"PHASE2","title":"CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)","status":"COMPLETED","sponsor":"InterMune","startDate":"2004-04","conditions":"Chronic Hepatitis C","enrollment":81},{"nctId":"NCT00887081","phase":"PHASE4","title":"Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies","status":"UNKNOWN","sponsor":"Azienda Ospedaliera V. Cervello","startDate":"2009-01","conditions":"Hemoglobinopathies","enrollment":150},{"nctId":"NCT00842205","phase":"NA","title":"Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection","status":"UNKNOWN","sponsor":"Charles University, Czech Republic","startDate":"2007-01","conditions":"Chronic HCV Infection, Nonalcoholic Steatohepatitis","enrollment":150},{"nctId":"NCT00351871","phase":"PHASE4","title":"Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy","status":"COMPLETED","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2002-04","conditions":"Chronic Hepatitis C","enrollment":400},{"nctId":"NCT00543244","phase":"","title":"Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2006-01","conditions":"Chronic Hepatitis C","enrollment":300},{"nctId":"NCT00723242","phase":"NA","title":"The Role of Dendritic Cells in Hepatitis C Infection","status":"COMPLETED","sponsor":"University College, London","startDate":"2002-04","conditions":"Chronic Hepatitis C Infection","enrollment":""},{"nctId":"NCT00277758","phase":"PHASE1","title":"Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2004-03","conditions":"Hepatitis C","enrollment":18},{"nctId":"NCT00277862","phase":"PHASE4","title":"Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2002-04","conditions":"Hepatitis C","enrollment":280},{"nctId":"NCT00148837","phase":"PHASE2","title":"Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis","status":"UNKNOWN","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2004-09","conditions":"Hepatitis C, Chronic, Fibrosis","enrollment":112},{"nctId":"NCT00088504","phase":"PHASE2","title":"Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2004-07","conditions":"Hepatitis C, Hepatitis","enrollment":315},{"nctId":"NCT00148863","phase":"PHASE2","title":"Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2004-06","conditions":"Hepatitis C, Chronic","enrollment":65},{"nctId":"NCT00299936","phase":"PHASE3","title":"Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Naïve Subjects","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"","conditions":"Chronic Hepatitis C","enrollment":5000},{"nctId":"NCT00122629","phase":"PHASE3","title":"Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders","status":"TERMINATED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2000-10","conditions":"Hepatitis C, Chronic","enrollment":405}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Peg interferon alfa 2b (Peg Intron)"],"phase":"marketed","status":"active","brandName":"Ribavirin, Peg interferon alfa 2b","genericName":"Ribavirin, Peg interferon alfa 2b","companyName":"Brooke Army Medical Center","companyId":"brooke-army-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ribavirin and peginterferon alfa-2b work together to inhibit viral replication and enhance immune response against hepatitis C virus. Used for Chronic hepatitis C virus infection (genotype-dependent), Hepatitis C in patients with compensated cirrhosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}